# ASCO-like Scorecard Generation Results (Single LLM Approach)

Date Generated: 2025-05-07 12:00:00

---

## Scorecard 1: Enzalutamide Versus Placebo After Chemotherapy in Metastatic Adenocarcinoma of Prostate

**Scenario Hint:** A trial of a novel hormone therapy against placebo in advanced prostate cancer after chemotherapy. Focus on Overall Survival. Hypothesize a plausible positive outcome with some expected toxicities and potential for bonus points typical for such a scenario.

| Measure                     | Result/Score                                                                                                          |
|-----------------------------|-----------------------------------------------------------------------------------------------------------------------|
| **Clinical Benefit Score**  | (1 – 0.75) × 100 × 1 = 25 → **25**                                                                                      |
| **Toxicity Score**          | ((25% ÷ 15%) – 1) × 20 = ((25/15 – 1) × 20) ≈ (1.6667 – 1) × 20 ≈ 0.6667 × 20 ≈ **–13.33**                             |
| **Bonus Points**            | Tail of the Curve: **10** <br> Palliation: **5** <br> Treatment-Free Interval: **3** <br> Health-related QoL: **5**        |
| **Total Bonus Points**      | 10 + 5 + 3 + 5 = **23**                                                                                                  |
| **Net Health Benefit**      | 25 + (–13.33) + 23 = **34.67**                                                                                           |
| **Cost (High monthly cost)**| High monthly cost                                                                                                       |

---

## Scorecard 2: Doxorubicin + Cyclophosphamide → Paclitaxel + Trastuzumab vs Doxorubicin + Cyclophosphamide + Paclitaxel in Adjuvant HER2+ Breast Cancer

**Scenario Hint:** A trial comparing a Trastuzumab-containing regimen against a standard chemotherapy regimen in adjuvant HER2+ breast cancer. Focus on Overall Survival. Hypothesize a plausible outcome, considering the impact of a targeted therapy like Trastuzumab.

| Measure                   | Result/Score                                                                                                                                       |
|---------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|
| **Clinical Benefit Score** | ((1 – 0.75) * 100 * 1) = (0.25 * 100 * 1) = **25**                                                                                                 |
| **Toxicity Score**         | (((18 / 14) – 1) * 20) = ((1.2857 – 1) * 20) ≈ **-5.71** (to be subtracted due to increased toxicity)                                              |
| **Bonus Points**           | Tail of the Curve: **10** <br> Palliation: **0** <br> Treatment-Free Interval: **0** <br> Health-related QoL: **5**                                |
| **Total Bonus Points**     | 10 + 0 + 0 + 5 = **15**                                                                                                                            |
| **Net Health Benefit**     | 25 + (–5.71) + 15 = **34.29**                                                                                                                      |
| **Cost (High monthly cost)** | High monthly cost (reflecting the expense of Trastuzumab in the adjuvant setting)                                                                |

---

## Scorecard 3: Ipilimumab Versus Placebo After Primary Treatment of Stage III Melanoma

**Scenario Hint:** A trial of an immunotherapy (Ipilimumab) versus placebo in the adjuvant setting for Stage III melanoma. Focus on Disease-Free Survival (DFS). Hypothesize a plausible outcome, considering typical efficacy and toxicity profiles for older immunotherapies in this setting. Toxicity might be a significant factor.

| Measure                   | Result/Score                                                                                                                                       |
|---------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|
| **Clinical Benefit Score** | (1 – 0.75) × 100 × 1 = 0.25 × 100 = **25**                                                                                                         |
| **Toxicity Score**         | ((18 / 5) – 1) × 20 = ((3.6 – 1) × 20) = 2.6 × 20 = **-52** (penalty for higher toxicity)                                                          |
| **Bonus Points**           | Tail of the Curve: **10**<br>Palliation: **0**<br>Treatment-Free Interval: **0**<br>Health-related QoL: **5**                                      |
| **Total Bonus Points**     | 10 + 0 + 0 + 5 = **15**                                                                                                                            |
| **Net Health Benefit**     | 25 + (–52) + 15 = (25 + 15) – 52 = 40 – 52 = **–12**                                                                                               |
| **Cost (Monthly/Overall)** | High monthly cost with a very high total course cost                                                                                               |

---

## Scorecard 4: Ibrutinib Versus Chlorambucil As Initial Therapy for Chronic Lymphocytic Leukemia

**Scenario Hint:** A trial comparing a newer targeted therapy (Ibrutinib) against an older chemotherapy agent (Chlorambucil) as first-line treatment for Chronic Lymphocytic Leukemia. Focus on Overall Survival. Hypothesize a plausible significant benefit for the newer agent, but also consider its unique toxicity profile.

| Measure                     | Result/Score                                                                                     |
|-----------------------------|--------------------------------------------------------------------------------------------------|
| **Clinical Benefit Score**  | (1 – 0.70) * 100 * 1 = 0.30 * 100 = **30**                                                       |
| **Toxicity Score**          | ((30% / 25%) – 1) * 20 = (1.2 – 1) * 20 = 0.2 * 20 = **–4**                                      |
| **Bonus Points**            | Tail of the Curve: **12**                                                                        |
|                             | Palliation: **5**                                                                                |
|                             | Treatment-Free Interval: **0**                                                                   |
|                             | Health-related QoL: **7**                                                                        |
| **Total Bonus Points**      | 12 + 5 + 0 + 7 = **24**                                                                          |
| **Net Health Benefit**      | 30 + (–4) + 24 = **50**                                                                          |
| **Cost (Relative Context)** | High monthly cost (reflects significant cumulative total cost over time compared with standard therapy) |

---
